FDA determines GLP-1s not linked to suicidal thoughts or actions in preliminary review
The FDA found that the use of GLP-1s to treat diabetes and obesity do not cause suicidal thoughts or actions in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.